The Entrepreneurs Fund BV has invested EUR 1.35m in the second closing of a series-A funding round for biotechnology company ProtAffin Biotechnologie AG. Previously, Aescap Venture Management BV and Z-Cube Srl invested EUR 2.65m in the first series-A closing in May 2007. This brings the total funds raised in the series-A financing to EUR 4m. The seed financing of EUR 1.3m was provided by angel investors and Austria Wirtschaftsservice in Vienna. ProtAffin Biotechnology AG is a pre-clinical biotechnology company developing protein-based products targeting inflammation. Its novel class of biologics targets heparin-like glycan structures driving inflammatory processes. ProtAffin was spun-out from the Karl-Franzens University of Graz, Austria in July 2005. It is headquartered in Graz, Austria, and currently has 12 employees.
Majority investment from THL Partners sees Verdane retain a minority stake in the Swedish company
GP to acquire majority stake via Fund VIII; German group’s founders to reinvest in the deal
German GP’s new vehicle will be slightly larger than its predecessor, which is set to complete deployment in two years
Italian GP has received EUR 230m in commitments to date for Fund V against a EUR 250m hard-cap